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DOI 10.1016/j.stem.2010.11.015Induced pluripotent stem cell (iPSC) tech-
nology, i.e. reprogramming somatic cells
into pluripotent cells that closely resemble
embryonic stem cells (ESCs) by introduc-
tion of defined transcription factors (TFs),
holds great potential in biomedical re-
search and regenerative medicine (Taka-
hashi and Yamanaka, 2006; Takahashi
et al., 2007; Yu et al., 2007). Various
strategies have been developed to
generate iPSCs with fewer or no exoge-
nous genetic manipulations, which repre-
sent a major hurdle for iPSC applications
(Yamanaka, 2009). With the ultimate goal
of generating iPSCs with a defined small
molecule cocktail alone, substantial effort
and progress have been made in identi-
fying chemical compounds that can
functionally replace exogenous reprog-
ramming TFs and/or enhance the effi-
ciency and kinetics of reprogramming
(Shi et al., 2008; Huangfu et al., 2008;
Lyssiotis et al., 2009; Ichida et al., 2009;
Maherali and Hochedlinger, 2009; Lin
et al., 2009; Li et al., 2009; Esteban
et al., 2010). To date, only neural stem
cells (NSCs), which endogenously ex-
press SOX2 and cMYC at a high level,
have been reprogrammed to iPSCs by
exogenous expression of just OCT4 (Kim
et al., 2009). However, human fetal
NSCs are rare and difficult to obtain.
It is therefore important to develop re-
programming conditions for other more
accessible somatic cells. Here we report
a small molecule cocktail that enables re-
programming of human primary somatic
cells to iPSCs with exogenous expression
of only OCT4. In addition, mechanistic
studies revealed that modulation of cell
metabolism from mitochondrial oxidation
to glycolysis plays an important role in
reprogramming.
Among several readily available primary
human somatic cell types, keratinocytes
can be isolated easily from human skinor hair follicle, and therefore represent
an attractive cell source for reprogram-
ming. Keratinocytes also endogenously
express KLF4 and cMYC, and can be re-
programmed efficiently using the conven-
tional four TFs or three TFs (without
cMYC) (Aasen et al., 2008; Maherali et al.,
2008). More recently, we reported that
dual inhibition of TGFb and MAPK/
ERK pathways using small molecules
(SB431542 and PD0325901, respectively)
provided significantly enhanced condi-
tions for reprogramming of human fibro-
blasts with the four TFs (i.e., OSKM)
(Lin et al., 2009). We have also shown
that this dual pathway inhibition can
also enhance reprogramming of human
keratinocytes by two exogenous TFs
(i.e., OK) with two small molecules,
Parnate (an inhibitor of lysine-specific de-
methylase 1) and CHIR99021 (a GSK3
inhibitor) (Li et al., 2009). With a goal of
OCT4-only reprogramming, we devel-
oped a stepwise strategy for refining
reprogramming conditions and identifying
additional small molecules that enhance
reprogramming.
We first attempted to further optimize
the reprogramming process using four or
three TFs (i.e., OSKM or OSK) in neonatal
human epidermal keratinocytes (NHEKs)
by testing various inhibitors of TGFb and
MAPK pathways at different concentra-
tions using previously reported human
iPSC characterization methods (Lin et al.,
2009). Encouragingly, we found that the
combination of 0.5 mM A-83-01 (a more
potent and selective TGFb receptor inhib-
itor) and 0.5 mM PD0325901 was more
effective than previous small molecule
combinations at enhancing reprogram-
ming of human keratinocytes transduced
with OSKM or OSK (Figure 1A). Remark-
ably, when we reduced the viral transduc-
tion to only two factors (OK), we could still
generate iPSCs from NHEKs when theyCell Stem Cell 7,were treated with 0.5 mM A-83-01 and
0.5 mM PD0325901, although with low
efficiency.We then began screening addi-
tional small molecules from a collection of
known bioactive compounds at various
concentrations as previously reported
(Shi et al., 2008). Among more than 50
compounds tested, we found that a small
molecule activator of 30-phosphoinosi-
tide-dependent kinase-1 (PDK1), PS48
(5 mM), which has not previously been
reported to have reprogramming activity,
can enhance reprogramming efficiency
by about 15-fold. Interestingly, we also
found that 0.25 mM sodium butyrate
(NaB, a histone deacetylase inhibitor) is
much more reliable and efficient than the
previously reported 0.5 mM VPA for the
generation of iPSCs under OK conditions
(Figure 1B). Subsequent follow-up studies
demonstrated that a combination of 5 mM
PS48 and 0.25 mM NaB could further
enhance the reprogramming efficiency
over 25-fold (Figure 1B).
With such high efficiency of reprogram-
ming NHEKs with two TFs, we explored
the possibility of generating iPSCs with
OCT4 alone by refining combinations of
these small molecules during different
treatment windows. Primary NHEKs were
transduced with OCT4 and treated
with the chemicals. We found that small
TRA-1-81-positive iPSC colonies resem-
bling hESCs (four to six colonies out of
1,000,000 seeded cells) appeared in
OCT4-infected NHEKs that were treated
with 0.25 mM NaB, 5 mM PS48, and
0.5 mM A-83-01 during the first 4 weeks,
followed by treatment with 0.25 mM
NaB, 5 mM PS48, 0.5 mM A-83-01, and
0.5 mM PD0325901 for another 4 weeks.
These TRA-1-81-positive iPSC colonies
grew larger in conventional hESC culture
media and could be serially passaged to
yield stable iPSC clones that were char-
acterized further. We also found thatDecember 3, 2010 ª2010 Elsevier Inc. 651
Figure 1. Generation and Characterizations of Human-Induced Pluripotent Stem Cells from Primary Somatic Cells by a Single Gene, OCT4,
and Small Molecules
(A) Treatment with 0.5 mM A-83-01 (A83) and 0.5 mM PD0325901 (PD) significantly improved generation of iPSCs from primary human keratinocytes transduced
with either four TFs (4F, OKSM) or three TFs (3F, OKS). NHEKs were seeded at a density of 100,000 transduced cells per 10 cm dish.
(B) Further chemical screens identified PS48, NaB, and their combination as compounds that can substantially enhance reprogramming of primary human ker-
atinocytes transduced with two TFs (OK). NHEKs were seeded at a density of 100,000 transduced cells per 10 cm dish.
(C) The established human iPSC-O cells by OCT4 and small molecules from NHEKs and HUVECs express typical pluripotency markers, including NANOG (red),
SOX2 (red), and SSEA4 (red). Nuclei were stained with DAPI (blue).
(D) Methylation analysis of theOCT4 and NANOG promoters by bisulfate genomic sequencing. Open circles and closed circles indicate unmethylated andmeth-
ylated CpGs, respectively, in the promoter regions.
(E) Scatter plots comparing global gene expression patterns between hiPSC-O cells and NHEKs, and hESCs. The positions of the pluripotency genes OCT4,
NANOG, and SOX2 are shown by arrows. Red lines indicate the linear equivalent and 2-fold changes in gene expression levels between the samples.
(F) Human iPSC-O cells could effectively differentiate in vitro into cells in the three germ layers, including neural ectodermal cells (bIII tubulin+), mesodermal cells
(SMA+), and endodermal cells (AFP+), using the EB method.
(G) Human iPSC-O cells could effectively produce full teratoma, which contained differentiated cells in the three germ layers, in SCIDmice. See also Figures S1
and S2, Tables S1 and S2, and Movie S1.
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from adult human epidermal keratino-
cytes (AHEKs) by addition of 2 mMParnate
and 3 mM CHIR99021 (which had been
shown to improve reprogramming of652 Cell Stem Cell 7, December 3, 2010 ª20NHEKs under OK condition) to this chem-
ical cocktail (Table S1 available online).
After this successful reprogramming of
primary human keratinocytes to iPSCs
by OCT4 and small molecules, we applied10 Elsevier Inc.the same conditions to other human
primary cell types, including humanumbil-
ical vein endothelial cells (HUVECs) and
amniotic fluid-derived cells (AFDCs). Like-
wise, TRA-1-81-positive iPSC colonies
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AFDCs that were treated with chemicals
for 5–6 weeks. Remarkably, reprogram-
ming of HUVECs and AFDCs was more
efficient and faster than reprogramming
of NHEKs using the OCT4 and small
molecules protocol (Table S1). Finally,
two clones of iPSC-O cells from each cell
type were expanded for over 20 passages
under conventional hESC culture condi-
tion and characterized further (Table S2).
The stably expanded hiPSC-O cells
were morphologically indistinguishable
from hESCs, stained positive for alkaline
phosphatase (ALP), and expressed
typical pluripotency markers, including
OCT4, SOX2, NANOG, TRA-1-81, and
SSEA4, as detected by immunocyto-
chemistry (ICC) (Figures 1C, S1A, S1C,
and data not shown). In addition, RT-
PCR analysis confirmed the expression
of the endogenous human OCT4, SOX2,
NANOG, REX1, UTF1, TDGF2, and FGF4
genes, and the silencing of exogenous
OCT4 (Figure S2A available online).
Furthermore, bisulfite sequencing anal-
ysis revealed that the OCT4 and NANOG
promoters of hiPSC-O cells are largely
demethylated, providing further evidence
for reactivation of the pluripotency tran-
scription program in these cells (Fig-
ure 1D). Global gene expression analysis
of hiPSC-O cells, NHEKs, and hESCs
showed that hiPSC-O cells are distinct
from NHEKs (Pearson correlation value:
0.87) and most similar to hESCs (Pearson
correlation value: 0.98) (Figure 1E). Geno-
typing analysis showed that hiPSC-O
cells only contained the OCT4 transgene
without the contamination of transgenes
KLF4 or SOX2 (Figure S2B). Karyotyping
results demonstrated that hiPSC-O main-
tained a normal karyotype during the
whole reprogramming and expansion
process (Figure S2C), and DNA finger-
printing tests excluded the possibility
that they arose from hESC contamination
in the laboratory (Figure S2D).
To examine the developmental poten-
tial of the hiPSC-O cells, they were
differentiated in vitro using a standard
embryoid body (EB) differentiation ap-
proach. ICC analyses demonstrated that
the hiPSC-O cells could effectively differ-
entiate into characteristic bIII-tubulin+
neuronal cells (ectoderm), SMA+ meso-
dermal cells, and AFP+ endodermal cells
(Figures 1F, S1B, and S1D). Quantitative
PCR analyses further confirmed theexpression of these and additional
lineage-specific marker genes char-
acteristic of ectodermal (bIII-tubulin and
NESTIN), mesodermal (MSX1 and
MLC2a), and endodermal (FOXA2 and
AFP) cells (data not shown). After the EB
protocol, the hiPSC-O cells could also
give rise to rhythmically beating cardio-
myocytes (Movie S1 available online). To
test the in vivo pluripotency of the cells,
they were transplanted into SCID mice.
After 4–6 weeks, the hiPSC-O cells effec-
tively generated typical teratomas con-
taining derivatives of all three germ layers
(Figure 1G). Collectively, these in vitro and
in vivo characterizations demonstrated
that a single transcription factor, OCT4,
combined with a defined small molecule
cocktail is sufficient to reprogram several
human primary somatic cell types to
iPSCs that are morphologically, molecu-
larly, and functionally similar to pluripotent
hESCs.
We then investigated the molecular
mechanism of action of the PDK1 acti-
vator PS48 in enhancing reprogramming.
It has been shown that differentiated
somatic cells typically use mitochondrial
oxidation while pluripotent cells mainly
use glycolysis for cell proliferation
(Manning and Cantley, 2007; Kondoh
et al., 2007; Vander Heiden et al., 2009;
Prigione et al., 2010). Therefore, genera-
tion of iPSCs would appear to involve
metabolic reprogramming from mito-
chondrial oxidation to glycolysis. Differ-
ential use of glycolytic metabolism
over mitochondrial oxidation by pluripo-
tent cells would favor pluripotency by
promoting proliferation/cell cycle transi-
tions with less oxidative stress. In addi-
tion, in highly proliferating cells oxidative
phosphorylation would not be able to
meet the demand of providing macromo-
lecular precursors for cell replication, and
would also generate a significant amount
of reactive oxygen species that could
induce excessive oxidative damages. On
the other hand, glycolytic metabolism
could more effectively generate macro-
molecular precursors, such as glycolytic
intermediates for nonessential amino
acids and acetyl-CoA for fatty acids, while
providing sufficient energy to meet the
needs of proliferating cells (Kondoh
et al., 2007; Vander Heiden et al., 2009).
In addition, growth factor signaling path-
ways-AKT activation, hypoxic conditions/
HIF-1a, and the reprogramming factorCell Stem Cell 7,MYC all regulate various aspects of
cellular metabolism, including the upregu-
lation of glucose transporters and meta-
bolic enzymes of glycolysis, such as
GLUT1, HK2, and PFK1 (Gordan et al.,
2007; DeBerardinis et al., 2008). Interest-
ingly, a hypoxic environment and its
effector, HIF-1a activation, both of which
have been closely linked to promoting
glycolytic metabolism, were reported to
improve reprogramming efficiency for
both mouse and human cells (Yoshida
et al., 2009). Moreover, MYC expression/
activity was also shown to play an
essential role in promoting glycolytic
metabolism and promoting reprogram-
ming efficiency (Vander Heiden et al.,
2009). Together, these studies suggested
that one potential mechanism of MYC,
hypoxic condition/HIF-1a, and growth
factor/AKT pathway activation in enhanc-
ing reprogramming could involve con-
verging on an essential role in regulating
glycolytic metabolism.
Because PS48 is an allosteric small
molecule activator of PDK1 that can lead
to downstream AKT activation (Hindie
et al., 2009), we hypothesized that PS48
may facilitate a metabolic conversion
frommitochondrial oxidation to glycolysis
during the reprogramming process, as
discussed above. Supporting this notion,
we found that treatment with PS48 acti-
vated downstream AKT/PKB (Figure 2A),
upregulated expression of several key
glycolytic genes (Figure 2D), and conse-
quently enhanced glycolysis as mea-
sured by increased lactate production
(Figure 2E). The effects of PS48 on
promoting reprogramming and conver-
sion to glycolysis could be blocked
by either a specific PDK1 inhibitor (UCN-
01) or a specific glycolysis inhibitor
(2-Deoxy-D-glucose, or 2-DG) (Figures
2B and 2E). Consistently, we also found
that UCN-01 inhibited glycolytic gene
expression in NHEKs (Figure 2D), and
either UCN-01 or 2-DG on their own
blocked the reprogramming process
(Figure 2C). Importantly, and consistent
with the idea that somatic cells differen-
tially use mitochondrial oxidation for cell
proliferation, inhibition of glycolysis by
2-DG did not affect somatic cell prolifera-
tion (Figure 2F). This result ruled out the
possibility that the glycolysis inhibitor’s
effect on reprogramming results from
an effect on cell growth/viability. In addi-
tion, a time course study on glycolysisDecember 3, 2010 ª2010 Elsevier Inc. 653
Figure 2. A Metabolic Switch toward Glycolysis Facilitates Reprogramming
(A) PS48 treatment activated PDK1 activity. The phosphorylation of AKT (Thr-308) after PS48 (5 mM) or UCN-01(20 nM) treatment was analyzed by western blot-
ting.
(B) PS48 enhanced reprogramming of NHEKs, while UCN-01 (20 nM) or 2-Deoxy-D-glucose (2-DG) (10 mM) inhibited PS48’s reprogramming enhancing effect.
OSK-transduced NHEKs were seeded at a density of 100,000 cells per well and treated with compounds for 4 weeks, and then TRA-1-81-positive colonies were
counted.
(C) The time course study of chemical treatment on reprogramming. OSK-transduced NHEKs were seeded at a density of 100,000 cells per well and treated with
compounds for different times, and then TRA-1-81-positive colonies were counted at the end of 4 weeks after transduction.
(D) Chemical treatment affected the expression of several key glycolytic genes, including GLUT1, HK2, PFK1, and LDHA.
(E) PS48 treatment facilitated/activated a metabolic switch to glycolysis, while its effect could be blocked by UCN-01 or 2-DG. NHEKs were treated with
compounds for 8 days and then lactate production in the medium was measured as a typical index of glycolysis.
(F) Inhibition of glycolysis by 2-DG did not affect the cell proliferation of somatic cells. NHEKs were treated with DMSO (control) or 2-DG, and cell number was
counted at the indicated time points.
(G) Known small molecules that have beenwidely used tomodulate mitochondrial oxidation, glycolysis metabolism, or HIF activation also showed corresponding
consistent effects on reprogramming. OSKM-transduced HUVECs were seeded at a density of 20,000 cells per well and treated with the metabolism modulating
compounds for 3 weeks, and TRA-1-81-positive colonies were counted. F2,6P, 10 mM Fructose 2,6-bisphosphate; F6P, 10 mM Fructose 6-phosphate; 6-AN,
10 mM6-aminonicotinamide; OA, 10 mMoxalate; DNP, 1 mM2,4-dinitrophenol; NOG, 1 mMN-oxaloylglycine; QC, 1 mMQuercetin; 2-HA, 10 mM2-Hydroxyglutaric
acid; NA, 10 mM nicotinic acid. DMSO was used as a control.
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vealed that only 8 day treatment with
these glycolysis modulators was suffi-
cient to affect reprogramming efficiency
(Figure 2C). This finding suggests that
early steps in the reprogramming process
were affected by these specific glycolysis
modulators because there were no iPSCs
generated at this time point (8 days).
Moreover, several known small molecules
that have been widely used to modu-
late mitochondrial oxidation (2,4-dinitro-
phenol), glycolytic metabolism (Fructose
2,6-bisphosphate and oxalate), or more
specifically HIF pathway activation (N-ox-
aloylglycine and Quercetin) also showed
corresponding effects on reprogramming:
i.e., compounds that promote glycolytic
metabolism enhance reprogramming654 Cell Stem Cell 7, December 3, 2010 ª20(such as 2,4-dinitrophenol and N-oxaloyl-
glycine), whereas compounds that block
glycolytic metabolism inhibit reprogram-
ming (such as oxalate) (Figure 2G) (Hewit-
son and Schofield, 2004; Pelicano et al.,
2006). In conclusion, these results collec-
tively indicated that a metabolic switch to
anaerobic glycolysis is an important step
in reprogramming somatic cells to plurip-
otent stem cells.
These studies have a number of impor-
tant implications: (1) although human fetal
NSCs were previously reprogrammed to
iPSCs by ectopic expression of OCT4
alone, our study now shows that iPSCs
can be derived from readily available
primary human somatic cells (e.g., kerati-
nocytes) transduced with a single exoge-
nous reprogramming gene, OCT4. (2) The10 Elsevier Inc.identification of small molecule cocktail
that we used, which functionally replaces
three master TFs all together (i.e., SOX2,
KLF4, and MYC) in enabling the genera-
tion of iPSCswith OCT4 alone, represents
an additional step toward the overall
goal of reprogramming with only small
molecules. (3) One way in which PS48
enhances reprogramming appears to
be facilitating the metabolic conversion
from mitochondrial oxidation, which is
mainly used by adult somatic cells, to
glycolysis, which is mainly used by plurip-
otent cells. Modulation of cellularmetabo-
lism by small molecules to either enhance
reprogramming or inhibit pluripotent cell
proliferation may well have additional
applications in the future development of
iPSC technology.
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